Paper Details

  1. Home
  2. Paper Details

Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.

Author: DeGregorioM W, HammJ T, KohlerP C, ShemanoI, TormeyD C, WiebeV J

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Toremifene, a triphenylethylene derivative, is a potential treatment for breast cancer. It causes common side effects like nausea, hot flashes, and dizziness. Steady-state concentrations are reached within 4 weeks, with a half-life of 5 days. Partial responses were seen in four patients, including three with breast cancer and one with endometrial cancer.
Paper Details　
Original Abstract of the Article :
Toremifene is a triphenylethylene derivative structurally and pharmacologically similar to tamoxifen. This Phase I trial assessed the safety, pharmacokinetics, anti-estrogenic, and estrogenic effects of toremifene at six dose levels (10, 20, 40, 60, 200, and 400 mg/day). The most common side-effects...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF01807140

データ提供：米国国立医学図書館（NLM）

Toremifene: A New Hope for Cancer Treatment?

Cancer, like a relentless desert wind, can sweep through the body, leaving behind devastation. Toremifene, a triphenylethylene derivative, has emerged as a potential therapeutic agent for certain types of cancer. This Phase I study investigates the safety, pharmacokinetics, and anti-estrogenic effects of toremifene at various dose levels. The researchers analyzed data from patients with cancer, assessing the drug's tolerance, side effects, and ability to block estrogen activity. The study also evaluated toremifene's potential as a treatment for specific cancers, such as breast and endometrial cancer.

Toremifene: A Promising Agent with Potential Side Effects

The study reveals that toremifene is generally well-tolerated, with the most common side effects being gastrointestinal, anti-estrogenic, and CNS-related. However, the study also notes that hypercalcemia may occur in patients with bone metastases from breast cancer. At doses greater than or equal to 40 mg/day, toremifene exhibited a dose-dependent estrogenic blockade, suggesting its potential in treating hormone-sensitive cancers.

Navigating the Terrain of Cancer Treatment

Cancer treatment is a complex and individualized process. While toremifene shows promise, it is crucial to discuss the potential benefits and risks with a qualified oncologist. Understanding the specific type of cancer and the patient's overall health status is essential for making informed treatment decisions.

Dr. Camel's Conclusion

This Phase I study provides initial insights into the safety, pharmacokinetics, and potential therapeutic effects of toremifene. While promising, further research is needed to fully evaluate its effectiveness and safety in treating various types of cancer.

Date :
  1. Date Completed 1991-03-21
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

2149280

DOI: Digital Object Identifier

10.1007/BF01807140

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.